{"gene":"ELL","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1996,"finding":"ELL encodes an RNA polymerase II elongation factor that increases the catalytic rate of transcription by suppressing transient pausing by polymerase at multiple sites along the DNA.","method":"In vitro transcription elongation assay using purified ELL protein","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution assay demonstrating enzymatic elongation activity, foundational paper replicated by multiple subsequent studies","pmids":["8596958"],"is_preprint":false},{"year":1994,"finding":"ELL was identified as the gene fusing to MLL in the t(11;19)(q23;p13.1) translocation in acute myeloid leukemia; the predicted ELL protein contains a highly basic, lysine-rich motif homologous to the DNA-binding domain of poly(ADP-ribose) polymerase.","method":"PCR screening of cDNA library, Northern blot analysis, sequence analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — cloning and characterization with multiple orthogonal methods (PCR, Northern blot, sequence analysis), independently replicated","pmids":["7991593"],"is_preprint":false},{"year":1997,"finding":"ELL contains two overlapping functional domains: an elongation activation domain and a novel RNA polymerase II interaction domain that negatively regulates polymerase activity in promoter-specific transcription initiation in vitro. The MLL-ELL translocation deletes part of this inhibitory domain, resulting in ELL mutants that bind RNA Pol II and are fully active in elongation but fail to inhibit initiation.","method":"In vitro transcription assay with deletion mutants, RNA polymerase II binding assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mutagenesis/deletion analysis, single lab with multiple orthogonal methods","pmids":["9268387"],"is_preprint":false},{"year":1997,"finding":"Murine ELL protein localizes to the nucleus but is excluded from nucleoli in COS-7, HeLa, NIH 3T3, and A7r5 cells, consistent with its function as an RNA polymerase II elongation factor.","method":"Immunofluorescence with polyclonal antiserum to ELL; in situ hybridization for developmental expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization experiment across multiple cell lines, single lab","pmids":["9037066"],"is_preprint":false},{"year":1998,"finding":"ELL exists in a large multi-protein complex (Holo-ELL complex) containing three additional proteins. The Holo-ELL complex stimulates RNA polymerase II elongation but, unlike ELL alone, cannot negatively regulate polymerase activity in promoter-specific transcription in vitro, indicating that associated proteins suppress the inhibitory activity of ELL through interaction with its N-terminal domain.","method":"Biochemical purification of native ELL complex; in vitro transcription assay comparing ELL polypeptide vs. Holo-ELL complex","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — purification and reconstitution of complex with in vitro functional comparison, single lab with multiple orthogonal methods","pmids":["9556611"],"is_preprint":false},{"year":1999,"finding":"ELL physically interacts with the p53 tumor suppressor protein via its transcription elongation activation domain (interacting with the C-terminal tail of p53). Through this interaction, ELL inhibits p53-dependent transactivation and transrepression; conversely, p53 inhibits ELL elongation activity. Elevated ELL suppresses p53-mediated p21 induction and protects cells from p53-dependent apoptosis.","method":"Yeast two-hybrid screening, co-immunoprecipitation, in vitro transcription assay, cell-based apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — yeast two-hybrid identification confirmed by functional in vitro assays and cellular assays, single lab with multiple orthogonal methods","pmids":["10358050"],"is_preprint":false},{"year":2000,"finding":"MLL-ELL fusion protein immortalizes myeloid progenitors and causes acute myeloid leukemia in mice. The transcriptional elongation domain of ELL is dispensable for myeloid transformation, whereas the highly conserved carboxyl-terminal R4 domain of ELL is both necessary and sufficient for MLL-ELL immortalizing activity. The R4 domain has transcriptional activation properties and is required for HoxA7 promoter transactivation by MLL-ELL.","method":"Retroviral transduction of murine hematopoietic progenitors, serial replating assay, bone marrow transplantation, structure-function mutagenesis, transient transcriptional assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro and in vivo functional assays with structure-function mutagenesis, replicated across in vitro and mouse model systems","pmids":["11090074"],"is_preprint":false},{"year":2000,"finding":"Retroviral transduction of MLL-ELL into murine hematopoietic progenitors causes acute myeloid leukemia in mice, demonstrating the causal oncogenic role of the fusion protein. ELL overexpression alone had no transforming effect.","method":"Retroviral transduction, bone marrow transplantation, in vitro serial replating assay, in vivo leukemia model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse model with in vitro controls, independently replicated by other groups","pmids":["10995463"],"is_preprint":false},{"year":2001,"finding":"The EAF1 interaction domain of ELL (but not the elongation domain) is critical for MLL-ELL immortalization of myeloid progenitors in vitro and AML induction in vivo. A heterologous MLL-EAF1 fusion also immortalizes myeloid progenitors and induces AML, indicating that recruitment of EAF1 (or its transactivation domain) is a critical function of ELL in MLL-ELL leukemogenesis.","method":"Structure-function mutagenesis of MLL-ELL, retroviral transduction, bone marrow transplantation mouse model, in vitro myeloid transformation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal domain swap experiments confirmed in vitro and in vivo, multiple orthogonal approaches","pmids":["11463848"],"is_preprint":false},{"year":2001,"finding":"EAF1 (ELL-associated factor 1) was identified as an ELL-binding protein by yeast two-hybrid screen; endogenous EAF1 and ELL co-immunoprecipitate from multiple cell lines and colocalize in a distinct nuclear speckled pattern. EAF1 also interacts with ELL2. Expression of MLL-ELL fusion protein delocalizes EAF1 from nuclear speckles to a diffuse nucleoplasmic pattern.","method":"Yeast two-hybrid screen, co-immunoprecipitation, confocal microscopy, transfection experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and confocal localization in multiple cell lines, single lab with multiple orthogonal methods","pmids":["11418481"],"is_preprint":false},{"year":2001,"finding":"ELL regulates cell proliferation and survival: inducible ELL expression causes G1 loss, G2/M accumulation, caspase-3 activation, PARP cleavage, and apoptosis. The C-terminal domain conserved among ELL family members is required for this activity.","method":"Inducible ELL expression system, flow cytometry, caspase activity assay, antisense RNA rescue, caspase inhibitor rescue","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean inducible KO/OE with defined phenotypic readout and rescue experiments, single lab","pmids":["11238904"],"is_preprint":false},{"year":2002,"finding":"EAF2 (ELL-associated factor 2) was identified as a second ELL-binding protein; ELL and EAF2 co-immunoprecipitate and colocalize in nuclear speckles. Unlike EAF1, EAF2 binds to the amino-terminus (not C-terminus) of ELL, and this amino-terminal ELL interaction domain is disrupted by the MLL-ELL fusion, abolishing EAF2 (but not EAF1) binding to MLL-ELL. Both EAF1 and EAF2 contain transcriptional activation domains.","method":"Co-immunoprecipitation, confocal microscopy, domain mapping, retroviral myeloid transformation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and domain mapping with functional validation, single lab with multiple orthogonal methods","pmids":["12446457"],"is_preprint":false},{"year":2003,"finding":"ELL and EAF1 are components of Cajal bodies (CBs) and colocalize with the CB marker p80 coilin, but without direct physical interaction with coilin. Localization of ELL and EAF1 in CBs is dependent on active RNA polymerase II transcription. MLL-ELL expression disrupts CBs, delocalizing EAF1 and p80 coilin.","method":"Immunofluorescence, confocal microscopy, Pol II inhibitor treatments (actinomycin D, DRB, alpha-amanitin), nuclear/cytoplasmic fractionation","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct localization with functional consequence established by pharmacological perturbation, multiple orthogonal methods in single lab","pmids":["12686606"],"is_preprint":false},{"year":2003,"finding":"MLL-ELL is a more efficient inhibitor of p53 than wild-type ELL. The extreme C-terminus of ELL (ELL eCT) is required for recruitment of p53 into MLL-ELL nuclear foci and is both necessary and sufficient for MLL-ELL inhibition of p53-mediated p21 induction and apoptosis. MLL-ELL requires intact ELL eCT to disrupt p53 interactions with p300/CBP and to reduce p53 acetylation in vivo.","method":"Deletion/mutant analysis, co-immunoprecipitation, luciferase reporter assay, in vivo acetylation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — structure-function mutagenesis combined with co-IP and functional cellular assays, single lab with multiple orthogonal methods","pmids":["12773566"],"is_preprint":false},{"year":2005,"finding":"EAF1 and EAF2 are strong positive regulators of ELL elongation activity. They bind ELL and stimulate its ability to increase the overall rate of RNA polymerase II elongation.","method":"In vitro transcription elongation assay, protein interaction studies","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution assay demonstrating functional stimulation, single lab with biochemical validation","pmids":["16006523"],"is_preprint":false},{"year":2005,"finding":"ELL physically interacts with the mineralocorticoid receptor (MR) N-terminal domain and functions as a coactivator that increases MR transcriptional potency. ELL differentially modulates steroid receptor responses, acting as a coactivator for MR but with opposite (inhibitory) effects on glucocorticoid receptor-mediated transactivation, without affecting androgen or progesterone receptor transactivation. Both the elongation domain and EAF1 interaction domain of ELL are required for this selective coregulator activity.","method":"Yeast two-hybrid, GST pull-down, co-immunoprecipitation, transient transfection reporter assays, ELL truncation/point mutants","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — interaction confirmed by multiple methods (Y2H, GST pulldown, Co-IP) with functional validation by reporter assay and structure-function analysis, single lab","pmids":["15650021"],"is_preprint":false},{"year":2001,"finding":"TFIIF, ELL, and Elongin negatively regulate SII-induced nascent transcript cleavage by non-arrested RNA polymerase II elongation intermediates, suggesting these factors suppress pausing by preventing displacement of the nascent transcript 3'-end from the polymerase catalytic site.","method":"In vitro transcription cleavage assay with purified factors","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution assay with purified components, mechanistic characterization, single lab","pmids":["11259417"],"is_preprint":false},{"year":2009,"finding":"ELL directly binds to the TSP-1 (thrombospondin-1) promoter and acts as a transcription factor to directly induce TSP-1 gene transcription. The DNA-binding domain maps to the first 45 amino acids of ELL; the C-terminus contains the transactivation domain. MLL-ELL, which lacks these N-terminal amino acids, does not induce TSP-1 expression. ELL regulates TSP-1 mRNA expression in vivo (zebrafish) and inhibits vasculogenesis through TSP-1 upregulation.","method":"Promoter reporter assay, deletion mutant analysis, ChIP, zebrafish in vivo model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo assays with deletion mutants and ChIP, single lab","pmids":["19447890"],"is_preprint":false},{"year":2006,"finding":"ELL binding to U19/Eaf2 is required for nuclear speckle formation of U19/Eaf2, stabilizes U19/Eaf2 protein, and enhances its transactivation activity.","method":"Co-transfection, co-immunoprecipitation, protein stability assay, transactivation reporter assay","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and functional assays for stability and transactivation, single lab with multiple orthogonal methods","pmids":["16114057"],"is_preprint":false},{"year":2006,"finding":"An S. pombe ortholog of the ELL-EAF elongation factor complex (SpELL-SpEAF) was identified and shown to stimulate RNA polymerase II transcription elongation and pyrophosphorolysis. Deletion of the SpELL gene renders S. pombe sensitive to 6-azauracil, consistent with an elongation function.","method":"Bioinformatic identification, biochemical purification, in vitro transcription elongation and pyrophosphorolysis assay, genetic 6-azauracil sensitivity assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution assay for elongation, genetic assay in S. pombe, single lab","pmids":["17150956"],"is_preprint":false},{"year":2012,"finding":"ELL has a role in stabilizing RNA polymerase II recruitment/initiation and entry into the promoter-proximal pause site prior to its assembly into the super elongation complex (SEC). Loss of ELL destabilizes pre-initiation complexes and disrupts early elongation and promoter-proximal chromatin structure before AFF4 and other SEC components are recruited, resulting in reduced transcriptional activation of rapidly induced genes.","method":"ChIP, ChIP-seq, ELL knockdown, gene expression analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP and genomic assays with functional knockdown, single lab with multiple orthogonal methods","pmids":["22252557"],"is_preprint":false},{"year":2013,"finding":"ELL is a partner of the general transcription factor TFIIH and is recruited to UV-damaged chromatin in a Cdk7-dependent manner. ELL depletion strongly impairs RNA polymerase II transcription resumption after DNA lesion removal/gap filling and increases Pol II retention on chromatin during this process, identifying ELL as an essential player in transcription restart after DNA repair.","method":"Proteomic (unbiased) identification of TFIIH partners, ChIP after UV damage, ELL siRNA knockdown, RNA Pol II localization assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — unbiased proteomics identification confirmed by ChIP and functional knockdown with specific phenotypic readout, single lab with multiple orthogonal methods","pmids":["24127601"],"is_preprint":false},{"year":2016,"finding":"ELL functions as an E3 ubiquitin ligase that targets c-Myc for polyubiquitylation and proteasomal degradation. UbcH8 serves as the ubiquitin-conjugating enzyme (E2) in this pathway. Cysteine 595 is the active site; C595A mutation abolishes ELL-mediated c-Myc ubiquitination and degradation, and ELL-mediated c-Myc degradation inhibits c-Myc-dependent transcription, cell proliferation, and xenograft tumor growth.","method":"In vivo ubiquitination assay, co-immunoprecipitation, site-directed mutagenesis (C595A), cell proliferation assay, xenograft tumor model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — E3 ligase activity demonstrated with active-site mutagenesis, E2 identification, and in vivo tumor model; single lab with multiple orthogonal methods","pmids":["27009366"],"is_preprint":false},{"year":2020,"finding":"ELL stability is regulated by a coordinated pathway: p300-mediated site-specific acetylation increases ELL stability, while HDAC3-mediated deacetylation decreases it through polyubiquitylation by the E3 ubiquitin ligase Siah1. DBC1 competes with HDAC3 for the same binding sites on ELL, thereby increasing ELL acetylation and stability. Knockdown of DBC1 reduces ELL levels and expression of ELL target genes including those involved in glucose metabolism.","method":"Co-immunoprecipitation, acetylation assay, ubiquitination assay, siRNA knockdown, gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple co-IP and functional assays defining writer (p300), eraser (HDAC3), E3 ligase (Siah1), and competing regulator (DBC1) with functional gene expression readout; single lab with multiple orthogonal methods","pmids":["32152128"],"is_preprint":false},{"year":2011,"finding":"In C. elegans, the ELL ortholog ELL-1 and EAF-1 play important roles in fertility, survival, and body size regulation, at least in part through modulating cuticle collagen gene expression (dpy-3, dpy-13, sqt-3). Consistent with this, ELL overexpression in PC3 human prostate cancer cells also regulates collagen gene expression.","method":"C. elegans RNAi knockdown, mutant analysis, transgenic worms, cuticle structure analysis, gene expression assay in human cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic loss-of-function with defined phenotypic readout, replicated across C. elegans and human cell context","pmids":["21880729"],"is_preprint":false}],"current_model":"ELL is a multifunctional nuclear protein best characterized as an RNA polymerase II elongation factor that suppresses transient pausing to increase the catalytic rate of transcription; it also stabilizes Pol II at pause sites before super elongation complex assembly, participates in transcription restart after DNA repair via TFIIH, interacts with and is regulated by EAF1/EAF2 (which positively stimulate its elongation activity), acts as a selective coactivator for the mineralocorticoid receptor and an inhibitor of glucocorticoid receptor signaling, physically inhibits and is inhibited by p53, directly activates thrombospondin-1 transcription, and functions as an E3 ubiquitin ligase targeting c-Myc for proteasomal degradation; its stability is controlled by p300-mediated acetylation, HDAC3-mediated deacetylation, Siah1-mediated ubiquitylation, and competition by DBC1."},"narrative":{"mechanistic_narrative":"ELL is a nuclear RNA polymerase II elongation factor that increases the catalytic rate of transcription by suppressing transient pausing of polymerase along the DNA [PMID:8596958], in part by preventing displacement of the nascent transcript 3' end from the polymerase catalytic site [PMID:11259417]. It carries two overlapping activities: an elongation activation domain and an N-terminal RNA Pol II interaction domain that negatively regulates promoter-specific initiation [PMID:9268387]. ELL acts before super elongation complex assembly to stabilize Pol II recruitment, initiation, and entry into the promoter-proximal pause site, and its loss disrupts early elongation and activation of rapidly induced genes [PMID:22252557]. As a partner of TFIIH, ELL is recruited to UV-damaged chromatin in a Cdk7-dependent manner and is required for Pol II transcription restart after DNA repair [PMID:24127601]. ELL function is shaped by stable association with EAF1 and EAF2, which bind distinct ELL domains, colocalize with it in nuclear speckles and Cajal bodies, and positively stimulate its elongation activity [PMID:11418481, PMID:12446457, PMID:16006523, PMID:12686606]. Beyond its elongation role, ELL is a sequence-specific transcription factor that binds the thrombospondin-1 promoter via its N-terminal 45 residues to directly activate TSP-1 [PMID:19447890], a selective steroid receptor coregulator that coactivates the mineralocorticoid receptor while inhibiting the glucocorticoid receptor [PMID:15650021], and an E3 ubiquitin ligase that uses an active-site cysteine (C595) and the E2 UbcH8 to target c-Myc for proteasomal degradation, thereby restraining c-Myc-driven proliferation and tumor growth [PMID:27009366]. ELL reciprocally inhibits p53-dependent transactivation and apoptosis through its elongation activation domain, while p53 inhibits ELL elongation activity [PMID:10358050]. ELL protein stability is governed by a coordinated acetylation switch in which p300 acetylates and stabilizes ELL, HDAC3 deacetylates it to permit Siah1-mediated polyubiquitylation, and DBC1 competes with HDAC3 to preserve ELL levels [PMID:32152128]. ELL is also the gene fused to MLL in the t(11;19) translocation of acute myeloid leukemia [PMID:7991593]; the MLL-ELL fusion is oncogenic and immortalizes myeloid progenitors through the C-terminal R4/EAF1-interaction region rather than the elongation domain [PMID:11090074, PMID:10995463, PMID:11463848].","teleology":[{"year":1994,"claim":"Established ELL as a disease gene by identifying it as the MLL fusion partner in t(11;19) AML, framing all subsequent mechanistic work around how a normal protein becomes oncogenic.","evidence":"PCR cloning, Northern blot, and sequence analysis of the translocation breakpoint","pmids":["7991593"],"confidence":"High","gaps":["Did not define the normal biochemical function of ELL","DNA-binding motif homology was inferred from sequence, not tested"]},{"year":1996,"claim":"Defined the core biochemical activity of ELL as an RNA Pol II elongation factor that suppresses transient pausing, answering what the protein does enzymatically.","evidence":"In vitro transcription elongation assay with purified ELL","pmids":["8596958"],"confidence":"High","gaps":["Did not establish the in vivo gene targets","Mechanism of pause suppression not yet resolved"]},{"year":1997,"claim":"Resolved ELL into separable elongation-activation and Pol II-interaction/initiation-inhibition domains and showed the MLL-ELL fusion deletes the inhibitory domain, linking domain architecture to leukemogenesis.","evidence":"In vitro transcription and Pol II binding assays with deletion mutants; immunofluorescence localization","pmids":["9268387","9037066"],"confidence":"High","gaps":["Causal contribution of initiation inhibition to normal physiology unclear","Did not test whether domain loss alone drives transformation"]},{"year":1998,"claim":"Showed ELL operates within a larger Holo-ELL complex whose partners suppress its initiation-inhibitory activity, establishing that associated proteins regulate ELL function.","evidence":"Biochemical purification of native complex and comparative in vitro transcription assays","pmids":["9556611"],"confidence":"High","gaps":["Identities of all complex components not fully defined here","Physiological assembly state unknown"]},{"year":1999,"claim":"Connected ELL to tumor-suppressor signaling by demonstrating reciprocal inhibition between ELL and p53, providing a route by which elevated ELL promotes survival.","evidence":"Yeast two-hybrid, Co-IP, in vitro transcription, and cellular apoptosis assays","pmids":["10358050"],"confidence":"High","gaps":["In vivo relevance to tumorigenesis not established","Stoichiometry of ELL-p53 inhibition unclear"]},{"year":2000,"claim":"Demonstrated that MLL-ELL is causally oncogenic and that the elongation domain is dispensable while the conserved C-terminal R4 region is necessary and sufficient for transformation, redirecting the leukemia mechanism away from elongation.","evidence":"Retroviral transduction, serial replating, bone marrow transplantation, and structure-function mutagenesis in mice","pmids":["11090074","10995463"],"confidence":"High","gaps":["Molecular function of the R4 transactivation activity not defined","Did not yet identify the critical R4-binding partner"]},{"year":2001,"claim":"Identified EAF1/EAF2 as ELL partners and showed EAF1 recruitment is the critical transforming function in MLL-ELL leukemogenesis, explaining the R4 requirement.","evidence":"Yeast two-hybrid, reciprocal Co-IP, confocal microscopy, domain swaps, and myeloid transformation assays in mice","pmids":["11418481","11463848","11238904"],"confidence":"High","gaps":["Mechanism by which EAF transactivation drives Hox dysregulation incomplete","Normal role of ELL-induced cell cycle/apoptosis effects unresolved"]},{"year":2001,"claim":"Provided a mechanistic model for pause suppression by showing ELL, with TFIIF and Elongin, prevents SII-induced transcript cleavage by blocking displacement of the nascent 3' end.","evidence":"In vitro transcript cleavage assay with purified factors","pmids":["11259417"],"confidence":"High","gaps":["Did not establish this on natural templates in vivo","Relative contribution of each factor unquantified"]},{"year":2002,"claim":"Distinguished EAF1 and EAF2 by mapping them to opposite ELL termini and showing the MLL-ELL fusion selectively abolishes EAF2 binding, refining the partner-specificity model.","evidence":"Co-IP, confocal microscopy, and domain mapping","pmids":["12446457"],"confidence":"High","gaps":["Functional consequence of selective EAF2 loss in leukemia untested","Whether EAF1 and EAF2 act redundantly unresolved"]},{"year":2003,"claim":"Localized ELL and EAF1 to transcription-dependent Cajal bodies and showed MLL-ELL disrupts these structures, linking subnuclear organization to fusion-driven dysfunction.","evidence":"Immunofluorescence with Pol II inhibitors and fractionation","pmids":["12686606"],"confidence":"High","gaps":["Functional role of Cajal body localization in transcription unclear","Mechanism of recruitment without coilin interaction unknown"]},{"year":2003,"claim":"Showed MLL-ELL is a more potent p53 inhibitor and that the ELL extreme C-terminus recruits p53 and blocks its p300/CBP-dependent acetylation, mechanistically tying the fusion to survival signaling.","evidence":"Deletion analysis, Co-IP, luciferase reporters, and in vivo acetylation assays","pmids":["12773566"],"confidence":"High","gaps":["In vivo contribution of p53 inhibition to leukemia not quantified","Did not reconcile p53 inhibition with R4/EAF1-dependent transformation"]},{"year":2005,"claim":"Established EAF1/EAF2 as positive regulators of ELL elongation activity and revealed ELL as a selective steroid receptor coregulator, broadening its transcriptional roles beyond core elongation.","evidence":"In vitro elongation assays; yeast two-hybrid, GST pulldown, Co-IP, and reporter assays with ELL mutants","pmids":["16006523","15650021"],"confidence":"High","gaps":["Endogenous gene targets of MR coactivation not mapped","Basis for receptor selectivity (MR vs GR) unresolved"]},{"year":2006,"claim":"Showed ELL reciprocally stabilizes and activates its partner U19/Eaf2 and is required for its speckle localization, indicating mutual regulation within the ELL-EAF axis.","evidence":"Co-transfection, Co-IP, protein stability, and transactivation assays","pmids":["16114057"],"confidence":"Medium","gaps":["Stabilization mechanism not defined","Single-lab cellular overexpression context"]},{"year":2007,"claim":"Demonstrated functional conservation of the ELL-EAF elongation complex by reconstituting the S. pombe ortholog and showing genetic elongation defects, supporting an ancient core function.","evidence":"Bioinformatic identification, biochemical reconstitution, in vitro elongation/pyrophosphorolysis, and 6-azauracil sensitivity in fission yeast","pmids":["17150956"],"confidence":"Medium","gaps":["Conservation of non-elongation roles untested","Direct ortholog mapping to human gene targets absent"]},{"year":2009,"claim":"Revealed ELL as a sequence-specific transcription factor that directly activates TSP-1 and inhibits vasculogenesis, expanding its role beyond a generic elongation factor.","evidence":"Promoter reporters, deletion mutants, ChIP, and a zebrafish in vivo model","pmids":["19447890"],"confidence":"Medium","gaps":["Direct DNA binding by a defined recognition motif not structurally validated","Breadth of direct target genes unknown"]},{"year":2011,"claim":"Established conserved organismal roles for ELL in fertility, survival, body size, and collagen gene regulation using the C. elegans ortholog, connecting transcriptional function to physiology.","evidence":"C. elegans RNAi, mutants, transgenics, and parallel human prostate cell expression analysis","pmids":["21880729"],"confidence":"Medium","gaps":["Direct vs indirect control of collagen genes unresolved","Human physiological equivalence inferred from one cell line"]},{"year":2012,"claim":"Defined a pre-SEC role for ELL in stabilizing Pol II recruitment, initiation, and pause entry, placing ELL at an early checkpoint of rapid gene induction in vivo.","evidence":"ChIP, ChIP-seq, ELL knockdown, and gene expression analysis","pmids":["22252557"],"confidence":"High","gaps":["How ELL is initially recruited before SEC assembly unclear","Interplay with EAF partners at this step not dissected"]},{"year":2013,"claim":"Identified ELL as a TFIIH partner essential for transcription restart after DNA repair, linking elongation control to the genome maintenance response.","evidence":"Unbiased proteomics, ChIP after UV damage, and siRNA knockdown with Pol II retention readouts","pmids":["24127601"],"confidence":"High","gaps":["Direct ELL-TFIIH contact surface not mapped","Cdk7-dependence mechanism of recruitment incomplete"]},{"year":2016,"claim":"Discovered an entirely separate enzymatic activity—ELL as an E3 ubiquitin ligase degrading c-Myc—establishing a tumor-suppressive mode opposed to its MLL-fusion oncogenicity.","evidence":"In vivo ubiquitination, Co-IP, C595A active-site mutagenesis, E2 (UbcH8) identification, proliferation and xenograft assays","pmids":["27009366"],"confidence":"High","gaps":["Structural basis for ligase activity not defined","Other ELL ubiquitylation substrates unknown"]},{"year":2020,"claim":"Defined the post-translational control of ELL abundance via a p300/HDAC3/Siah1/DBC1 acetylation-ubiquitylation switch, explaining how ELL levels and its target genes are tuned.","evidence":"Co-IP, acetylation and ubiquitination assays, siRNA knockdown, and gene expression analysis","pmids":["32152128"],"confidence":"High","gaps":["Acetylated lysine residues not all pinpointed","Physiological signals triggering the switch unknown"]},{"year":null,"claim":"How ELL's distinct activities—elongation, sequence-specific transcription, steroid coregulation, and c-Myc E3 ligase—are partitioned and coordinated within cells, and how each contributes to normal physiology versus MLL-ELL disease, remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified structural model integrating elongation and E3 ligase functions","Endogenous genome-wide direct target set incompletely defined","Context determining which ELL activity dominates is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,17,15]},{"term_id":"GO:0045182","term_label":"translation regulator activity","supporting_discovery_ids":[0,16,14,20]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[22]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[22]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,15]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[9,12]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,20]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,6,7]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[22,23]}],"complexes":["Holo-ELL complex","ELL-EAF complex","super elongation complex (SEC)"],"partners":["EAF1","EAF2","TP53","TFIIH","MLL","UBCH8","SIAH1","HDAC3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P55199","full_name":"RNA polymerase II elongation factor ELL","aliases":["Eleven-nineteen lysine-rich leukemia protein"],"length_aa":621,"mass_kda":68.3,"function":"Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Elongation factor component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III (PubMed:22195968, PubMed:23932780). Specifically required for stimulating the elongation step of RNA polymerase II- and III-dependent snRNA gene transcription (PubMed:23932780). ELL also plays an early role before its assembly into in the SEC complex by stabilizing RNA polymerase II recruitment/initiation and entry into the pause site. Required to stabilize the pre-initiation complex and early elongation","subcellular_location":"Nucleus; Nucleus speckle; Nucleus, Cajal body","url":"https://www.uniprot.org/uniprotkb/P55199/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/ELL","classification":"Common Essential","n_dependent_lines":1147,"n_total_lines":1208,"dependency_fraction":0.9495033112582781},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ELL","total_profiled":1310},"omim":[{"mim_id":"617958","title":"INTERACTOR OF LITTLE ELONGATION COMPLEX ELL SUBUNIT 1; ICE1","url":"https://www.omim.org/entry/617958"},{"mim_id":"617470","title":"UBIQUITIN-SPECIFIC PEPTIDASE-LIKE 1; USPL1","url":"https://www.omim.org/entry/617470"},{"mim_id":"610907","title":"VACUOLAR PROTEIN SORTING 25 HOMOLOG; VPS25","url":"https://www.omim.org/entry/610907"},{"mim_id":"610904","title":"SNF8 SUBUNIT OF ESCRIT-II; SNF8","url":"https://www.omim.org/entry/610904"},{"mim_id":"610903","title":"VACUOLAR PROTEIN SORTING 36 HOMOLOG; VPS36","url":"https://www.omim.org/entry/610903"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ELL"},"hgnc":{"alias_symbol":["Men","ELL1","PPP1R68"],"prev_symbol":["C19orf17"]},"alphafold":{"accession":"P55199","domains":[{"cath_id":"-","chopping":"27-134","consensus_level":"high","plddt":85.3538,"start":27,"end":134},{"cath_id":"1.10.10.2670","chopping":"208-293","consensus_level":"high","plddt":89.6044,"start":208,"end":293},{"cath_id":"-","chopping":"514-620","consensus_level":"high","plddt":93.9492,"start":514,"end":620}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P55199","model_url":"https://alphafold.ebi.ac.uk/files/AF-P55199-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P55199-F1-predicted_aligned_error_v6.png","plddt_mean":67.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ELL","jax_strain_url":"https://www.jax.org/strain/search?query=ELL"},"sequence":{"accession":"P55199","fasta_url":"https://rest.uniprot.org/uniprotkb/P55199.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P55199/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P55199"}},"corpus_meta":[{"pmid":"16551248","id":"PMC_16551248","title":"FOXP3: of mice and men.","date":"2006","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16551248","citation_count":766,"is_preprint":false},{"pmid":"27664823","id":"PMC_27664823","title":"The role of masculinity in men's help-seeking for depression: A systematic review.","date":"2016","source":"Clinical psychology review","url":"https://pubmed.ncbi.nlm.nih.gov/27664823","citation_count":590,"is_preprint":false},{"pmid":"9147109","id":"PMC_9147109","title":"Cytogenetics of infertile men.","date":"1996","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9147109","citation_count":344,"is_preprint":false},{"pmid":"12379069","id":"PMC_12379069","title":"Breast cancer in men.","date":"2002","source":"Annals of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12379069","citation_count":315,"is_preprint":false},{"pmid":"6605701","id":"PMC_6605701","title":"Generalized lymphadenopathy in homosexual men.","date":"1983","source":"Annals of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6605701","citation_count":305,"is_preprint":false},{"pmid":"8596958","id":"PMC_8596958","title":"An RNA polymerase II elongation factor encoded by the human ELL gene.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8596958","citation_count":297,"is_preprint":false},{"pmid":"7991593","id":"PMC_7991593","title":"Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7991593","citation_count":207,"is_preprint":false},{"pmid":"17726542","id":"PMC_17726542","title":"Insulin resistance and body fat distribution in South Asian men compared to Caucasian men.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17726542","citation_count":191,"is_preprint":false},{"pmid":"16289741","id":"PMC_16289741","title":"Men's accounts of depression: reconstructing or resisting hegemonic masculinity?","date":"2005","source":"Social science & medicine (1982)","url":"https://pubmed.ncbi.nlm.nih.gov/16289741","citation_count":178,"is_preprint":false},{"pmid":"18923135","id":"PMC_18923135","title":"Idiopathic intracranial hypertension in men.","date":"2008","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18923135","citation_count":169,"is_preprint":false},{"pmid":"29641964","id":"PMC_29641964","title":"Zika Virus Shedding in Semen of Symptomatic Infected Men.","date":"2018","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29641964","citation_count":155,"is_preprint":false},{"pmid":"15669543","id":"PMC_15669543","title":"Progesterone: the forgotten hormone in men?","date":"2004","source":"The aging male : the official journal of the International Society for the Study of the Aging Male","url":"https://pubmed.ncbi.nlm.nih.gov/15669543","citation_count":152,"is_preprint":false},{"pmid":"25733578","id":"PMC_25733578","title":"Cohort Profile: The Shanghai Men's Health Study.","date":"2015","source":"International journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/25733578","citation_count":141,"is_preprint":false},{"pmid":"9403124","id":"PMC_9403124","title":"Declining gonadal function in elderly men.","date":"1997","source":"Bailliere's clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9403124","citation_count":124,"is_preprint":false},{"pmid":"10995463","id":"PMC_10995463","title":"Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10995463","citation_count":120,"is_preprint":false},{"pmid":"10374090","id":"PMC_10374090","title":"Genetic evaluation of infertile men.","date":"1999","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10374090","citation_count":118,"is_preprint":false},{"pmid":"28536242","id":"PMC_28536242","title":"Mutation in TDRD9 causes non-obstructive azoospermia in infertile men.","date":"2017","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28536242","citation_count":117,"is_preprint":false},{"pmid":"16792526","id":"PMC_16792526","title":"In control of biology: of mice, men and Foxes.","date":"2006","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16792526","citation_count":113,"is_preprint":false},{"pmid":"7757495","id":"PMC_7757495","title":"Brain spectrin: of mice and men.","date":"1995","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/7757495","citation_count":112,"is_preprint":false},{"pmid":"35504878","id":"PMC_35504878","title":"High-throughput single-сell sequencing in cancer research.","date":"2022","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35504878","citation_count":111,"is_preprint":false},{"pmid":"12045493","id":"PMC_12045493","title":"HIV, syphilis and heterosexual bridging among Peruvian men who have sex with men.","date":"2002","source":"AIDS (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12045493","citation_count":106,"is_preprint":false},{"pmid":"15385442","id":"PMC_15385442","title":"Defective recombination in infertile men.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15385442","citation_count":104,"is_preprint":false},{"pmid":"28853720","id":"PMC_28853720","title":"The Y chromosome: a blueprint for men's health?","date":"2017","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/28853720","citation_count":94,"is_preprint":false},{"pmid":"12573239","id":"PMC_12573239","title":"Chromosome cohesion and separation: from men and molecules.","date":"2003","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/12573239","citation_count":91,"is_preprint":false},{"pmid":"7938171","id":"PMC_7938171","title":"Pax: genes for mice and men.","date":"1994","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/7938171","citation_count":90,"is_preprint":false},{"pmid":"11090074","id":"PMC_11090074","title":"A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11090074","citation_count":88,"is_preprint":false},{"pmid":"16006523","id":"PMC_16006523","title":"ELL-associated factors 1 and 2 are positive regulators of RNA polymerase II elongation factor ELL.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16006523","citation_count":87,"is_preprint":false},{"pmid":"21123766","id":"PMC_21123766","title":"Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/21123766","citation_count":85,"is_preprint":false},{"pmid":"11463848","id":"PMC_11463848","title":"The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11463848","citation_count":82,"is_preprint":false},{"pmid":"11418481","id":"PMC_11418481","title":"EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11418481","citation_count":72,"is_preprint":false},{"pmid":"12446457","id":"PMC_12446457","title":"ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12446457","citation_count":72,"is_preprint":false},{"pmid":"25315188","id":"PMC_25315188","title":"Androgen receptor signaling regulates growth of glioblastoma multiforme in men.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25315188","citation_count":71,"is_preprint":false},{"pmid":"19836146","id":"PMC_19836146","title":"The human superorganism - of microbes and men.","date":"2010","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/19836146","citation_count":70,"is_preprint":false},{"pmid":"15711018","id":"PMC_15711018","title":"Diabetic cardiomyopathy: do women differ from men?","date":"2004","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/15711018","citation_count":70,"is_preprint":false},{"pmid":"15650021","id":"PMC_15650021","title":"The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions.","date":"2005","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15650021","citation_count":67,"is_preprint":false},{"pmid":"9268387","id":"PMC_9268387","title":"Structure and function of RNA polymerase II elongation factor ELL. Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9268387","citation_count":66,"is_preprint":false},{"pmid":"15959652","id":"PMC_15959652","title":"Men's decision-making about predictive BRCA1/2 testing: the role of family.","date":"2005","source":"Journal of genetic counseling","url":"https://pubmed.ncbi.nlm.nih.gov/15959652","citation_count":64,"is_preprint":false},{"pmid":"19140019","id":"PMC_19140019","title":"Myofilament dysfunction in cardiac disease from mice to men.","date":"2009","source":"Journal of muscle research and cell motility","url":"https://pubmed.ncbi.nlm.nih.gov/19140019","citation_count":64,"is_preprint":false},{"pmid":"12668350","id":"PMC_12668350","title":"The genes and brains of mice and men.","date":"2003","source":"The American journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12668350","citation_count":63,"is_preprint":false},{"pmid":"22189712","id":"PMC_22189712","title":"The power of MEN in cytokinesis.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22189712","citation_count":59,"is_preprint":false},{"pmid":"19154724","id":"PMC_19154724","title":"Cell polarity determinants establish asymmetry in MEN signaling.","date":"2009","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/19154724","citation_count":56,"is_preprint":false},{"pmid":"25336341","id":"PMC_25336341","title":"Epigenetic germline mosaicism in infertile men.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25336341","citation_count":49,"is_preprint":false},{"pmid":"19995647","id":"PMC_19995647","title":"Differential expression of biomarkers in men and women.","date":"2009","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19995647","citation_count":48,"is_preprint":false},{"pmid":"11228931","id":"PMC_11228931","title":"Differences in reproductive endocrinology between Asian men and Caucasian men--a literature review.","date":"2000","source":"Asian journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/11228931","citation_count":46,"is_preprint":false},{"pmid":"10358050","id":"PMC_10358050","title":"Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10358050","citation_count":46,"is_preprint":false},{"pmid":"36506029","id":"PMC_36506029","title":"Prevention and treatment of human papillomavirus in men benefits both men and women.","date":"2022","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36506029","citation_count":45,"is_preprint":false},{"pmid":"29673272","id":"PMC_29673272","title":"Critical Issues in Men's Mental Health.","date":"2018","source":"Canadian journal of psychiatry. Revue canadienne de psychiatrie","url":"https://pubmed.ncbi.nlm.nih.gov/29673272","citation_count":44,"is_preprint":false},{"pmid":"24337010","id":"PMC_24337010","title":"Functional consequences of EpCam mutation in mice and men.","date":"2013","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24337010","citation_count":44,"is_preprint":false},{"pmid":"24127601","id":"PMC_24127601","title":"ELL, a novel TFIIH partner, is involved in transcription restart after DNA repair.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24127601","citation_count":44,"is_preprint":false},{"pmid":"23212543","id":"PMC_23212543","title":"WNT signaling and cartilage: of mice and men.","date":"2012","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/23212543","citation_count":43,"is_preprint":false},{"pmid":"22252557","id":"PMC_22252557","title":"ELL facilitates RNA polymerase II pause site entry and release.","date":"2012","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/22252557","citation_count":42,"is_preprint":false},{"pmid":"19793749","id":"PMC_19793749","title":"Androgen receptor gene sequence and basal cortisol concentrations predict men's hormonal responses to potential mates.","date":"2009","source":"Proceedings. Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19793749","citation_count":42,"is_preprint":false},{"pmid":"15114471","id":"PMC_15114471","title":"Control of glycaemia: from molecules to men. Minkowski Lecture 2003.","date":"2004","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/15114471","citation_count":41,"is_preprint":false},{"pmid":"20032019","id":"PMC_20032019","title":"Of mice and men: comparative proteomics of bronchoalveolar fluid.","date":"2009","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/20032019","citation_count":41,"is_preprint":false},{"pmid":"2478611","id":"PMC_2478611","title":"Of matrices and men.","date":"1989","source":"Journal of biochemical and biophysical methods","url":"https://pubmed.ncbi.nlm.nih.gov/2478611","citation_count":39,"is_preprint":false},{"pmid":"12686606","id":"PMC_12686606","title":"ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia.","date":"2003","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/12686606","citation_count":38,"is_preprint":false},{"pmid":"27009366","id":"PMC_27009366","title":"ELL targets c-Myc for proteasomal degradation and suppresses tumour growth.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27009366","citation_count":38,"is_preprint":false},{"pmid":"32702096","id":"PMC_32702096","title":"Men with sickle cell disease experience greater sexual dysfunction when compared with men without sickle cell disease.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32702096","citation_count":36,"is_preprint":false},{"pmid":"12773566","id":"PMC_12773566","title":"Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12773566","citation_count":36,"is_preprint":false},{"pmid":"2399296","id":"PMC_2399296","title":"Anxiety and food intake in men.","date":"1990","source":"Psychosomatic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2399296","citation_count":35,"is_preprint":false},{"pmid":"11259417","id":"PMC_11259417","title":"Transcription factors TFIIF, ELL, and Elongin negatively regulate SII-induced nascent transcript cleavage by non-arrested RNA polymerase II elongation intermediates.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11259417","citation_count":34,"is_preprint":false},{"pmid":"9556611","id":"PMC_9556611","title":"Identification and purification of the Holo-ELL complex. Evidence for the presence of ELL-associated proteins that suppress the transcriptional inhibitory activity of ELL.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9556611","citation_count":33,"is_preprint":false},{"pmid":"22088127","id":"PMC_22088127","title":"Banking sperm is only the first of many decisions for men: what healthcare professionals and men need to know.","date":"2011","source":"Human fertility (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22088127","citation_count":33,"is_preprint":false},{"pmid":"18927127","id":"PMC_18927127","title":"USP26 gene variations in fertile and infertile men.","date":"2008","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18927127","citation_count":32,"is_preprint":false},{"pmid":"11238904","id":"PMC_11238904","title":"Functional analysis of the leukemia protein ELL: evidence for a role in the regulation of cell growth and survival.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11238904","citation_count":32,"is_preprint":false},{"pmid":"7655733","id":"PMC_7655733","title":"Multiple endocrine neoplasia type 1 (MEN 1) revisited.","date":"1995","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7655733","citation_count":32,"is_preprint":false},{"pmid":"19340391","id":"PMC_19340391","title":"Anxiety in mice and men: a comparison.","date":"2009","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/19340391","citation_count":30,"is_preprint":false},{"pmid":"24931355","id":"PMC_24931355","title":"Multiple endocrine neoplasia (MEN) syndromes.","date":"2014","source":"Seminars in pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/24931355","citation_count":29,"is_preprint":false},{"pmid":"23645088","id":"PMC_23645088","title":"Mitochondrial DNA mutations and polymorphisms in asthenospermic infertile men.","date":"2013","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23645088","citation_count":29,"is_preprint":false},{"pmid":"21880729","id":"PMC_21880729","title":"Regulation of fertility, survival, and cuticle collagen function by the Caenorhabditis elegans eaf-1 and ell-1 genes.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21880729","citation_count":29,"is_preprint":false},{"pmid":"30826898","id":"PMC_30826898","title":"Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?","date":"2019","source":"Current hypertension reports","url":"https://pubmed.ncbi.nlm.nih.gov/30826898","citation_count":28,"is_preprint":false},{"pmid":"10849016","id":"PMC_10849016","title":"Criteria for mutation analysis in MEN 1-suspected patients: MEN 1 case-finding.","date":"2000","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10849016","citation_count":28,"is_preprint":false},{"pmid":"30565412","id":"PMC_30565412","title":"Normobaric hypoxic conditioning in men with metabolic syndrome.","date":"2018","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/30565412","citation_count":28,"is_preprint":false},{"pmid":"25532417","id":"PMC_25532417","title":"Insulin resistance and depressive symptoms in older men: the health in men study.","date":"2014","source":"The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/25532417","citation_count":26,"is_preprint":false},{"pmid":"24696767","id":"PMC_24696767","title":"Chromosomal abnormality in men with impaired spermatogenesis.","date":"2014","source":"International journal of fertility & sterility","url":"https://pubmed.ncbi.nlm.nih.gov/24696767","citation_count":26,"is_preprint":false},{"pmid":"9866208","id":"PMC_9866208","title":"Y chromosome variation of mice and men.","date":"1998","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/9866208","citation_count":26,"is_preprint":false},{"pmid":"19447890","id":"PMC_19447890","title":"Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19447890","citation_count":25,"is_preprint":false},{"pmid":"17150956","id":"PMC_17150956","title":"Identification and Characterization of a Schizosaccharomyces pombe RNA Polymerase II Elongation Factor with Similarity to the Metazoan Transcription Factor ELL.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17150956","citation_count":25,"is_preprint":false},{"pmid":"18681990","id":"PMC_18681990","title":"Altered expression of progesterone receptors in testis of infertile men.","date":"2008","source":"Reproductive biomedicine online","url":"https://pubmed.ncbi.nlm.nih.gov/18681990","citation_count":25,"is_preprint":false},{"pmid":"36231089","id":"PMC_36231089","title":"Of Flies and Men-The Discovery of TLRs.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36231089","citation_count":24,"is_preprint":false},{"pmid":"30202739","id":"PMC_30202739","title":"What should be done for men with sperm DNA fragmentation?","date":"2018","source":"Clinical and experimental reproductive medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30202739","citation_count":24,"is_preprint":false},{"pmid":"9037066","id":"PMC_9037066","title":"Developmental analysis and subcellular localization of the murine homologue of ELL.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9037066","citation_count":23,"is_preprint":false},{"pmid":"14517999","id":"PMC_14517999","title":"Expression of murine ELL-associated factor 2 (Eaf2) is developmentally regulated.","date":"2003","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/14517999","citation_count":21,"is_preprint":false},{"pmid":"29972105","id":"PMC_29972105","title":"Neuropsychiatric Aspects in Men with Klinefelter Syndrome.","date":"2019","source":"Endocrine, metabolic & immune disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/29972105","citation_count":21,"is_preprint":false},{"pmid":"30626059","id":"PMC_30626059","title":"Bisphenol A Exposure and Sperm ACHE Hydroxymethylation in Men.","date":"2019","source":"International journal of environmental research and public health","url":"https://pubmed.ncbi.nlm.nih.gov/30626059","citation_count":21,"is_preprint":false},{"pmid":"26232868","id":"PMC_26232868","title":"Testosterone and reward prediction-errors in healthy men and men with schizophrenia.","date":"2015","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/26232868","citation_count":21,"is_preprint":false},{"pmid":"26393143","id":"PMC_26393143","title":"Chromosomal Abnormalities in Infertile Men from Southern India.","date":"2015","source":"Journal of clinical and diagnostic research : JCDR","url":"https://pubmed.ncbi.nlm.nih.gov/26393143","citation_count":21,"is_preprint":false},{"pmid":"32152128","id":"PMC_32152128","title":"DBC1, p300, HDAC3, and Siah1 coordinately regulate ELL stability and function for expression of its target genes.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32152128","citation_count":20,"is_preprint":false},{"pmid":"19272337","id":"PMC_19272337","title":"Gene doping: of mice and men.","date":"2009","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19272337","citation_count":20,"is_preprint":false},{"pmid":"1752062","id":"PMC_1752062","title":"Inhibin and age in men.","date":"1991","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/1752062","citation_count":20,"is_preprint":false},{"pmid":"29459712","id":"PMC_29459712","title":"The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29459712","citation_count":19,"is_preprint":false},{"pmid":"30884051","id":"PMC_30884051","title":"Testosterone-dependent facial and body traits predict men's sociosexual attitudes and behaviors.","date":"2019","source":"American journal of human biology : the official journal of the Human Biology Council","url":"https://pubmed.ncbi.nlm.nih.gov/30884051","citation_count":19,"is_preprint":false},{"pmid":"31412971","id":"PMC_31412971","title":"MicroRNA expression in infertile men: its alterations and effects.","date":"2019","source":"Zygote (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31412971","citation_count":18,"is_preprint":false},{"pmid":"20483870","id":"PMC_20483870","title":"Aging men and lipids.","date":"2010","source":"American journal of men's health","url":"https://pubmed.ncbi.nlm.nih.gov/20483870","citation_count":18,"is_preprint":false},{"pmid":"17824171","id":"PMC_17824171","title":"Of mice and men: the many guises of estrogens.","date":"2006","source":"Ernst Schering Foundation symposium proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/17824171","citation_count":18,"is_preprint":false},{"pmid":"16114057","id":"PMC_16114057","title":"ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation.","date":"2006","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/16114057","citation_count":18,"is_preprint":false},{"pmid":"21825313","id":"PMC_21825313","title":"Postnatal neurogenesis: of mice, men, and macaques.","date":"2011","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21825313","citation_count":17,"is_preprint":false},{"pmid":"34901258","id":"PMC_34901258","title":"Men's Help-Seeking for Distress: Navigating Varied Pathways and Practices.","date":"2021","source":"Frontiers in sociology","url":"https://pubmed.ncbi.nlm.nih.gov/34901258","citation_count":17,"is_preprint":false},{"pmid":"37457197","id":"PMC_37457197","title":"Anthocyanin and proanthocyanidin from Aronia melanocarpa (Michx.) Ell.: Purification, fractionation, and enzyme inhibition.","date":"2023","source":"Food science & nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/37457197","citation_count":16,"is_preprint":false},{"pmid":"34168527","id":"PMC_34168527","title":"The endocannabinoid system, cannabis, and cannabidiol: Implications in urology and men's health.","date":"2021","source":"Current urology","url":"https://pubmed.ncbi.nlm.nih.gov/34168527","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44624,"output_tokens":6122,"usd":0.112851,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14883,"output_tokens":5861,"usd":0.11047,"stage2_stop_reason":"end_turn"},"total_usd":0.223321,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"ELL encodes an RNA polymerase II elongation factor that increases the catalytic rate of transcription by suppressing transient pausing by polymerase at multiple sites along the DNA.\",\n      \"method\": \"In vitro transcription elongation assay using purified ELL protein\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution assay demonstrating enzymatic elongation activity, foundational paper replicated by multiple subsequent studies\",\n      \"pmids\": [\"8596958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ELL was identified as the gene fusing to MLL in the t(11;19)(q23;p13.1) translocation in acute myeloid leukemia; the predicted ELL protein contains a highly basic, lysine-rich motif homologous to the DNA-binding domain of poly(ADP-ribose) polymerase.\",\n      \"method\": \"PCR screening of cDNA library, Northern blot analysis, sequence analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cloning and characterization with multiple orthogonal methods (PCR, Northern blot, sequence analysis), independently replicated\",\n      \"pmids\": [\"7991593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ELL contains two overlapping functional domains: an elongation activation domain and a novel RNA polymerase II interaction domain that negatively regulates polymerase activity in promoter-specific transcription initiation in vitro. The MLL-ELL translocation deletes part of this inhibitory domain, resulting in ELL mutants that bind RNA Pol II and are fully active in elongation but fail to inhibit initiation.\",\n      \"method\": \"In vitro transcription assay with deletion mutants, RNA polymerase II binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mutagenesis/deletion analysis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"9268387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Murine ELL protein localizes to the nucleus but is excluded from nucleoli in COS-7, HeLa, NIH 3T3, and A7r5 cells, consistent with its function as an RNA polymerase II elongation factor.\",\n      \"method\": \"Immunofluorescence with polyclonal antiserum to ELL; in situ hybridization for developmental expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization experiment across multiple cell lines, single lab\",\n      \"pmids\": [\"9037066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ELL exists in a large multi-protein complex (Holo-ELL complex) containing three additional proteins. The Holo-ELL complex stimulates RNA polymerase II elongation but, unlike ELL alone, cannot negatively regulate polymerase activity in promoter-specific transcription in vitro, indicating that associated proteins suppress the inhibitory activity of ELL through interaction with its N-terminal domain.\",\n      \"method\": \"Biochemical purification of native ELL complex; in vitro transcription assay comparing ELL polypeptide vs. Holo-ELL complex\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — purification and reconstitution of complex with in vitro functional comparison, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"9556611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ELL physically interacts with the p53 tumor suppressor protein via its transcription elongation activation domain (interacting with the C-terminal tail of p53). Through this interaction, ELL inhibits p53-dependent transactivation and transrepression; conversely, p53 inhibits ELL elongation activity. Elevated ELL suppresses p53-mediated p21 induction and protects cells from p53-dependent apoptosis.\",\n      \"method\": \"Yeast two-hybrid screening, co-immunoprecipitation, in vitro transcription assay, cell-based apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — yeast two-hybrid identification confirmed by functional in vitro assays and cellular assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"10358050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MLL-ELL fusion protein immortalizes myeloid progenitors and causes acute myeloid leukemia in mice. The transcriptional elongation domain of ELL is dispensable for myeloid transformation, whereas the highly conserved carboxyl-terminal R4 domain of ELL is both necessary and sufficient for MLL-ELL immortalizing activity. The R4 domain has transcriptional activation properties and is required for HoxA7 promoter transactivation by MLL-ELL.\",\n      \"method\": \"Retroviral transduction of murine hematopoietic progenitors, serial replating assay, bone marrow transplantation, structure-function mutagenesis, transient transcriptional assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro and in vivo functional assays with structure-function mutagenesis, replicated across in vitro and mouse model systems\",\n      \"pmids\": [\"11090074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Retroviral transduction of MLL-ELL into murine hematopoietic progenitors causes acute myeloid leukemia in mice, demonstrating the causal oncogenic role of the fusion protein. ELL overexpression alone had no transforming effect.\",\n      \"method\": \"Retroviral transduction, bone marrow transplantation, in vitro serial replating assay, in vivo leukemia model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse model with in vitro controls, independently replicated by other groups\",\n      \"pmids\": [\"10995463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The EAF1 interaction domain of ELL (but not the elongation domain) is critical for MLL-ELL immortalization of myeloid progenitors in vitro and AML induction in vivo. A heterologous MLL-EAF1 fusion also immortalizes myeloid progenitors and induces AML, indicating that recruitment of EAF1 (or its transactivation domain) is a critical function of ELL in MLL-ELL leukemogenesis.\",\n      \"method\": \"Structure-function mutagenesis of MLL-ELL, retroviral transduction, bone marrow transplantation mouse model, in vitro myeloid transformation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal domain swap experiments confirmed in vitro and in vivo, multiple orthogonal approaches\",\n      \"pmids\": [\"11463848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"EAF1 (ELL-associated factor 1) was identified as an ELL-binding protein by yeast two-hybrid screen; endogenous EAF1 and ELL co-immunoprecipitate from multiple cell lines and colocalize in a distinct nuclear speckled pattern. EAF1 also interacts with ELL2. Expression of MLL-ELL fusion protein delocalizes EAF1 from nuclear speckles to a diffuse nucleoplasmic pattern.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, confocal microscopy, transfection experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and confocal localization in multiple cell lines, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"11418481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ELL regulates cell proliferation and survival: inducible ELL expression causes G1 loss, G2/M accumulation, caspase-3 activation, PARP cleavage, and apoptosis. The C-terminal domain conserved among ELL family members is required for this activity.\",\n      \"method\": \"Inducible ELL expression system, flow cytometry, caspase activity assay, antisense RNA rescue, caspase inhibitor rescue\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean inducible KO/OE with defined phenotypic readout and rescue experiments, single lab\",\n      \"pmids\": [\"11238904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"EAF2 (ELL-associated factor 2) was identified as a second ELL-binding protein; ELL and EAF2 co-immunoprecipitate and colocalize in nuclear speckles. Unlike EAF1, EAF2 binds to the amino-terminus (not C-terminus) of ELL, and this amino-terminal ELL interaction domain is disrupted by the MLL-ELL fusion, abolishing EAF2 (but not EAF1) binding to MLL-ELL. Both EAF1 and EAF2 contain transcriptional activation domains.\",\n      \"method\": \"Co-immunoprecipitation, confocal microscopy, domain mapping, retroviral myeloid transformation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and domain mapping with functional validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"12446457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ELL and EAF1 are components of Cajal bodies (CBs) and colocalize with the CB marker p80 coilin, but without direct physical interaction with coilin. Localization of ELL and EAF1 in CBs is dependent on active RNA polymerase II transcription. MLL-ELL expression disrupts CBs, delocalizing EAF1 and p80 coilin.\",\n      \"method\": \"Immunofluorescence, confocal microscopy, Pol II inhibitor treatments (actinomycin D, DRB, alpha-amanitin), nuclear/cytoplasmic fractionation\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization with functional consequence established by pharmacological perturbation, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"12686606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MLL-ELL is a more efficient inhibitor of p53 than wild-type ELL. The extreme C-terminus of ELL (ELL eCT) is required for recruitment of p53 into MLL-ELL nuclear foci and is both necessary and sufficient for MLL-ELL inhibition of p53-mediated p21 induction and apoptosis. MLL-ELL requires intact ELL eCT to disrupt p53 interactions with p300/CBP and to reduce p53 acetylation in vivo.\",\n      \"method\": \"Deletion/mutant analysis, co-immunoprecipitation, luciferase reporter assay, in vivo acetylation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structure-function mutagenesis combined with co-IP and functional cellular assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"12773566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"EAF1 and EAF2 are strong positive regulators of ELL elongation activity. They bind ELL and stimulate its ability to increase the overall rate of RNA polymerase II elongation.\",\n      \"method\": \"In vitro transcription elongation assay, protein interaction studies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution assay demonstrating functional stimulation, single lab with biochemical validation\",\n      \"pmids\": [\"16006523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ELL physically interacts with the mineralocorticoid receptor (MR) N-terminal domain and functions as a coactivator that increases MR transcriptional potency. ELL differentially modulates steroid receptor responses, acting as a coactivator for MR but with opposite (inhibitory) effects on glucocorticoid receptor-mediated transactivation, without affecting androgen or progesterone receptor transactivation. Both the elongation domain and EAF1 interaction domain of ELL are required for this selective coregulator activity.\",\n      \"method\": \"Yeast two-hybrid, GST pull-down, co-immunoprecipitation, transient transfection reporter assays, ELL truncation/point mutants\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — interaction confirmed by multiple methods (Y2H, GST pulldown, Co-IP) with functional validation by reporter assay and structure-function analysis, single lab\",\n      \"pmids\": [\"15650021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TFIIF, ELL, and Elongin negatively regulate SII-induced nascent transcript cleavage by non-arrested RNA polymerase II elongation intermediates, suggesting these factors suppress pausing by preventing displacement of the nascent transcript 3'-end from the polymerase catalytic site.\",\n      \"method\": \"In vitro transcription cleavage assay with purified factors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution assay with purified components, mechanistic characterization, single lab\",\n      \"pmids\": [\"11259417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ELL directly binds to the TSP-1 (thrombospondin-1) promoter and acts as a transcription factor to directly induce TSP-1 gene transcription. The DNA-binding domain maps to the first 45 amino acids of ELL; the C-terminus contains the transactivation domain. MLL-ELL, which lacks these N-terminal amino acids, does not induce TSP-1 expression. ELL regulates TSP-1 mRNA expression in vivo (zebrafish) and inhibits vasculogenesis through TSP-1 upregulation.\",\n      \"method\": \"Promoter reporter assay, deletion mutant analysis, ChIP, zebrafish in vivo model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo assays with deletion mutants and ChIP, single lab\",\n      \"pmids\": [\"19447890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ELL binding to U19/Eaf2 is required for nuclear speckle formation of U19/Eaf2, stabilizes U19/Eaf2 protein, and enhances its transactivation activity.\",\n      \"method\": \"Co-transfection, co-immunoprecipitation, protein stability assay, transactivation reporter assay\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and functional assays for stability and transactivation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16114057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"An S. pombe ortholog of the ELL-EAF elongation factor complex (SpELL-SpEAF) was identified and shown to stimulate RNA polymerase II transcription elongation and pyrophosphorolysis. Deletion of the SpELL gene renders S. pombe sensitive to 6-azauracil, consistent with an elongation function.\",\n      \"method\": \"Bioinformatic identification, biochemical purification, in vitro transcription elongation and pyrophosphorolysis assay, genetic 6-azauracil sensitivity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution assay for elongation, genetic assay in S. pombe, single lab\",\n      \"pmids\": [\"17150956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ELL has a role in stabilizing RNA polymerase II recruitment/initiation and entry into the promoter-proximal pause site prior to its assembly into the super elongation complex (SEC). Loss of ELL destabilizes pre-initiation complexes and disrupts early elongation and promoter-proximal chromatin structure before AFF4 and other SEC components are recruited, resulting in reduced transcriptional activation of rapidly induced genes.\",\n      \"method\": \"ChIP, ChIP-seq, ELL knockdown, gene expression analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and genomic assays with functional knockdown, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22252557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ELL is a partner of the general transcription factor TFIIH and is recruited to UV-damaged chromatin in a Cdk7-dependent manner. ELL depletion strongly impairs RNA polymerase II transcription resumption after DNA lesion removal/gap filling and increases Pol II retention on chromatin during this process, identifying ELL as an essential player in transcription restart after DNA repair.\",\n      \"method\": \"Proteomic (unbiased) identification of TFIIH partners, ChIP after UV damage, ELL siRNA knockdown, RNA Pol II localization assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — unbiased proteomics identification confirmed by ChIP and functional knockdown with specific phenotypic readout, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24127601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ELL functions as an E3 ubiquitin ligase that targets c-Myc for polyubiquitylation and proteasomal degradation. UbcH8 serves as the ubiquitin-conjugating enzyme (E2) in this pathway. Cysteine 595 is the active site; C595A mutation abolishes ELL-mediated c-Myc ubiquitination and degradation, and ELL-mediated c-Myc degradation inhibits c-Myc-dependent transcription, cell proliferation, and xenograft tumor growth.\",\n      \"method\": \"In vivo ubiquitination assay, co-immunoprecipitation, site-directed mutagenesis (C595A), cell proliferation assay, xenograft tumor model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — E3 ligase activity demonstrated with active-site mutagenesis, E2 identification, and in vivo tumor model; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"27009366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ELL stability is regulated by a coordinated pathway: p300-mediated site-specific acetylation increases ELL stability, while HDAC3-mediated deacetylation decreases it through polyubiquitylation by the E3 ubiquitin ligase Siah1. DBC1 competes with HDAC3 for the same binding sites on ELL, thereby increasing ELL acetylation and stability. Knockdown of DBC1 reduces ELL levels and expression of ELL target genes including those involved in glucose metabolism.\",\n      \"method\": \"Co-immunoprecipitation, acetylation assay, ubiquitination assay, siRNA knockdown, gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple co-IP and functional assays defining writer (p300), eraser (HDAC3), E3 ligase (Siah1), and competing regulator (DBC1) with functional gene expression readout; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32152128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In C. elegans, the ELL ortholog ELL-1 and EAF-1 play important roles in fertility, survival, and body size regulation, at least in part through modulating cuticle collagen gene expression (dpy-3, dpy-13, sqt-3). Consistent with this, ELL overexpression in PC3 human prostate cancer cells also regulates collagen gene expression.\",\n      \"method\": \"C. elegans RNAi knockdown, mutant analysis, transgenic worms, cuticle structure analysis, gene expression assay in human cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic loss-of-function with defined phenotypic readout, replicated across C. elegans and human cell context\",\n      \"pmids\": [\"21880729\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ELL is a multifunctional nuclear protein best characterized as an RNA polymerase II elongation factor that suppresses transient pausing to increase the catalytic rate of transcription; it also stabilizes Pol II at pause sites before super elongation complex assembly, participates in transcription restart after DNA repair via TFIIH, interacts with and is regulated by EAF1/EAF2 (which positively stimulate its elongation activity), acts as a selective coactivator for the mineralocorticoid receptor and an inhibitor of glucocorticoid receptor signaling, physically inhibits and is inhibited by p53, directly activates thrombospondin-1 transcription, and functions as an E3 ubiquitin ligase targeting c-Myc for proteasomal degradation; its stability is controlled by p300-mediated acetylation, HDAC3-mediated deacetylation, Siah1-mediated ubiquitylation, and competition by DBC1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ELL is a nuclear RNA polymerase II elongation factor that increases the catalytic rate of transcription by suppressing transient pausing of polymerase along the DNA [#0], in part by preventing displacement of the nascent transcript 3' end from the polymerase catalytic site [#16]. It carries two overlapping activities: an elongation activation domain and an N-terminal RNA Pol II interaction domain that negatively regulates promoter-specific initiation [#2]. ELL acts before super elongation complex assembly to stabilize Pol II recruitment, initiation, and entry into the promoter-proximal pause site, and its loss disrupts early elongation and activation of rapidly induced genes [#20]. As a partner of TFIIH, ELL is recruited to UV-damaged chromatin in a Cdk7-dependent manner and is required for Pol II transcription restart after DNA repair [#21]. ELL function is shaped by stable association with EAF1 and EAF2, which bind distinct ELL domains, colocalize with it in nuclear speckles and Cajal bodies, and positively stimulate its elongation activity [#9, #11, #14, #12]. Beyond its elongation role, ELL is a sequence-specific transcription factor that binds the thrombospondin-1 promoter via its N-terminal 45 residues to directly activate TSP-1 [#17], a selective steroid receptor coregulator that coactivates the mineralocorticoid receptor while inhibiting the glucocorticoid receptor [#15], and an E3 ubiquitin ligase that uses an active-site cysteine (C595) and the E2 UbcH8 to target c-Myc for proteasomal degradation, thereby restraining c-Myc-driven proliferation and tumor growth [#22]. ELL reciprocally inhibits p53-dependent transactivation and apoptosis through its elongation activation domain, while p53 inhibits ELL elongation activity [#5]. ELL protein stability is governed by a coordinated acetylation switch in which p300 acetylates and stabilizes ELL, HDAC3 deacetylates it to permit Siah1-mediated polyubiquitylation, and DBC1 competes with HDAC3 to preserve ELL levels [#23]. ELL is also the gene fused to MLL in the t(11;19) translocation of acute myeloid leukemia [#1]; the MLL-ELL fusion is oncogenic and immortalizes myeloid progenitors through the C-terminal R4/EAF1-interaction region rather than the elongation domain [#6, #7, #8].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established ELL as a disease gene by identifying it as the MLL fusion partner in t(11;19) AML, framing all subsequent mechanistic work around how a normal protein becomes oncogenic.\",\n      \"evidence\": \"PCR cloning, Northern blot, and sequence analysis of the translocation breakpoint\",\n      \"pmids\": [\"7991593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the normal biochemical function of ELL\", \"DNA-binding motif homology was inferred from sequence, not tested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined the core biochemical activity of ELL as an RNA Pol II elongation factor that suppresses transient pausing, answering what the protein does enzymatically.\",\n      \"evidence\": \"In vitro transcription elongation assay with purified ELL\",\n      \"pmids\": [\"8596958\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the in vivo gene targets\", \"Mechanism of pause suppression not yet resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolved ELL into separable elongation-activation and Pol II-interaction/initiation-inhibition domains and showed the MLL-ELL fusion deletes the inhibitory domain, linking domain architecture to leukemogenesis.\",\n      \"evidence\": \"In vitro transcription and Pol II binding assays with deletion mutants; immunofluorescence localization\",\n      \"pmids\": [\"9268387\", \"9037066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal contribution of initiation inhibition to normal physiology unclear\", \"Did not test whether domain loss alone drives transformation\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed ELL operates within a larger Holo-ELL complex whose partners suppress its initiation-inhibitory activity, establishing that associated proteins regulate ELL function.\",\n      \"evidence\": \"Biochemical purification of native complex and comparative in vitro transcription assays\",\n      \"pmids\": [\"9556611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identities of all complex components not fully defined here\", \"Physiological assembly state unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Connected ELL to tumor-suppressor signaling by demonstrating reciprocal inhibition between ELL and p53, providing a route by which elevated ELL promotes survival.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, in vitro transcription, and cellular apoptosis assays\",\n      \"pmids\": [\"10358050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance to tumorigenesis not established\", \"Stoichiometry of ELL-p53 inhibition unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated that MLL-ELL is causally oncogenic and that the elongation domain is dispensable while the conserved C-terminal R4 region is necessary and sufficient for transformation, redirecting the leukemia mechanism away from elongation.\",\n      \"evidence\": \"Retroviral transduction, serial replating, bone marrow transplantation, and structure-function mutagenesis in mice\",\n      \"pmids\": [\"11090074\", \"10995463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular function of the R4 transactivation activity not defined\", \"Did not yet identify the critical R4-binding partner\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified EAF1/EAF2 as ELL partners and showed EAF1 recruitment is the critical transforming function in MLL-ELL leukemogenesis, explaining the R4 requirement.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal Co-IP, confocal microscopy, domain swaps, and myeloid transformation assays in mice\",\n      \"pmids\": [\"11418481\", \"11463848\", \"11238904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which EAF transactivation drives Hox dysregulation incomplete\", \"Normal role of ELL-induced cell cycle/apoptosis effects unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Provided a mechanistic model for pause suppression by showing ELL, with TFIIF and Elongin, prevents SII-induced transcript cleavage by blocking displacement of the nascent 3' end.\",\n      \"evidence\": \"In vitro transcript cleavage assay with purified factors\",\n      \"pmids\": [\"11259417\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish this on natural templates in vivo\", \"Relative contribution of each factor unquantified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Distinguished EAF1 and EAF2 by mapping them to opposite ELL termini and showing the MLL-ELL fusion selectively abolishes EAF2 binding, refining the partner-specificity model.\",\n      \"evidence\": \"Co-IP, confocal microscopy, and domain mapping\",\n      \"pmids\": [\"12446457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of selective EAF2 loss in leukemia untested\", \"Whether EAF1 and EAF2 act redundantly unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Localized ELL and EAF1 to transcription-dependent Cajal bodies and showed MLL-ELL disrupts these structures, linking subnuclear organization to fusion-driven dysfunction.\",\n      \"evidence\": \"Immunofluorescence with Pol II inhibitors and fractionation\",\n      \"pmids\": [\"12686606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of Cajal body localization in transcription unclear\", \"Mechanism of recruitment without coilin interaction unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed MLL-ELL is a more potent p53 inhibitor and that the ELL extreme C-terminus recruits p53 and blocks its p300/CBP-dependent acetylation, mechanistically tying the fusion to survival signaling.\",\n      \"evidence\": \"Deletion analysis, Co-IP, luciferase reporters, and in vivo acetylation assays\",\n      \"pmids\": [\"12773566\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of p53 inhibition to leukemia not quantified\", \"Did not reconcile p53 inhibition with R4/EAF1-dependent transformation\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established EAF1/EAF2 as positive regulators of ELL elongation activity and revealed ELL as a selective steroid receptor coregulator, broadening its transcriptional roles beyond core elongation.\",\n      \"evidence\": \"In vitro elongation assays; yeast two-hybrid, GST pulldown, Co-IP, and reporter assays with ELL mutants\",\n      \"pmids\": [\"16006523\", \"15650021\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous gene targets of MR coactivation not mapped\", \"Basis for receptor selectivity (MR vs GR) unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed ELL reciprocally stabilizes and activates its partner U19/Eaf2 and is required for its speckle localization, indicating mutual regulation within the ELL-EAF axis.\",\n      \"evidence\": \"Co-transfection, Co-IP, protein stability, and transactivation assays\",\n      \"pmids\": [\"16114057\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stabilization mechanism not defined\", \"Single-lab cellular overexpression context\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated functional conservation of the ELL-EAF elongation complex by reconstituting the S. pombe ortholog and showing genetic elongation defects, supporting an ancient core function.\",\n      \"evidence\": \"Bioinformatic identification, biochemical reconstitution, in vitro elongation/pyrophosphorolysis, and 6-azauracil sensitivity in fission yeast\",\n      \"pmids\": [\"17150956\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Conservation of non-elongation roles untested\", \"Direct ortholog mapping to human gene targets absent\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed ELL as a sequence-specific transcription factor that directly activates TSP-1 and inhibits vasculogenesis, expanding its role beyond a generic elongation factor.\",\n      \"evidence\": \"Promoter reporters, deletion mutants, ChIP, and a zebrafish in vivo model\",\n      \"pmids\": [\"19447890\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA binding by a defined recognition motif not structurally validated\", \"Breadth of direct target genes unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established conserved organismal roles for ELL in fertility, survival, body size, and collagen gene regulation using the C. elegans ortholog, connecting transcriptional function to physiology.\",\n      \"evidence\": \"C. elegans RNAi, mutants, transgenics, and parallel human prostate cell expression analysis\",\n      \"pmids\": [\"21880729\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect control of collagen genes unresolved\", \"Human physiological equivalence inferred from one cell line\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined a pre-SEC role for ELL in stabilizing Pol II recruitment, initiation, and pause entry, placing ELL at an early checkpoint of rapid gene induction in vivo.\",\n      \"evidence\": \"ChIP, ChIP-seq, ELL knockdown, and gene expression analysis\",\n      \"pmids\": [\"22252557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ELL is initially recruited before SEC assembly unclear\", \"Interplay with EAF partners at this step not dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified ELL as a TFIIH partner essential for transcription restart after DNA repair, linking elongation control to the genome maintenance response.\",\n      \"evidence\": \"Unbiased proteomics, ChIP after UV damage, and siRNA knockdown with Pol II retention readouts\",\n      \"pmids\": [\"24127601\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ELL-TFIIH contact surface not mapped\", \"Cdk7-dependence mechanism of recruitment incomplete\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovered an entirely separate enzymatic activity—ELL as an E3 ubiquitin ligase degrading c-Myc—establishing a tumor-suppressive mode opposed to its MLL-fusion oncogenicity.\",\n      \"evidence\": \"In vivo ubiquitination, Co-IP, C595A active-site mutagenesis, E2 (UbcH8) identification, proliferation and xenograft assays\",\n      \"pmids\": [\"27009366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for ligase activity not defined\", \"Other ELL ubiquitylation substrates unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the post-translational control of ELL abundance via a p300/HDAC3/Siah1/DBC1 acetylation-ubiquitylation switch, explaining how ELL levels and its target genes are tuned.\",\n      \"evidence\": \"Co-IP, acetylation and ubiquitination assays, siRNA knockdown, and gene expression analysis\",\n      \"pmids\": [\"32152128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetylated lysine residues not all pinpointed\", \"Physiological signals triggering the switch unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ELL's distinct activities—elongation, sequence-specific transcription, steroid coregulation, and c-Myc E3 ligase—are partitioned and coordinated within cells, and how each contributes to normal physiology versus MLL-ELL disease, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified structural model integrating elongation and E3 ligase functions\", \"Endogenous genome-wide direct target set incompletely defined\", \"Context determining which ELL activity dominates is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 17, 15]},\n      {\"term_id\": \"GO:0045182\", \"supporting_discovery_ids\": [0, 16, 14, 20]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [9, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 20]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 6, 7]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [22, 23]}\n    ],\n    \"complexes\": [\"Holo-ELL complex\", \"ELL-EAF complex\", \"super elongation complex (SEC)\"],\n    \"partners\": [\"EAF1\", \"EAF2\", \"TP53\", \"TFIIH\", \"MLL\", \"UbcH8\", \"Siah1\", \"HDAC3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":9,"faith_total":9,"faith_pct":100.0}}